Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 196

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 196
---
 patentable. To protect our rights, we plan to require employees, consultants, advisors and collaborators to enter into confidentiality
agreements. There can be no assurance, however, that these agreements will provide meaningful protection for our trade secrets, know-how
or other proprietary information in the event of any unauthorized use or disclosure. Further, our business may be adversely affected by
competitors who independently develop competing technologies, especially if we obtain no, or only narrow, patent protection.

If we fail to protect our intellectual property
rights, our ability to pursue the development of our technologies and products would be negatively affected. 

Our success will depend, in
part, on our ability to obtain patents and maintain adequate protection of our technologies and products. If we do not adequately protect
our intellectual property, competitors may be able to use our technologies to produce and market drugs in direct competition with us and
erode our competitive advantage. Some foreign countries lack rules and methods for defending intellectual property rights and do not protect
proprietary rights to the same extent as the United States. Many companies have had difficulty protecting their proprietary rights in
these foreign countries. We may not be able to prevent misappropriation of our proprietary rights.

We have received, and are
currently seeking, patent protection for numerous compounds and methods of treating diseases. However, the patent process is subject to
numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products by obtaining and
defending patents. These risks and uncertainties include the following: patents that may be issued or licensed may be challenged, invalidated,
or circumvented, or otherwise may not provide any competitive advantage; our competitors, many of which have substantially greater resources
than us and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents
that will limit, interfere with, or eliminate our ability to make, use, and sell our potential products either in the United States or
in international markets; there may be significant pressure on the United States government and other international governmental bodies
to limit the scope of patent protection both inside and outside the United States for treatments that prove successful as a matter of
public policy regarding worldwide health concerns; countries other than the United States may have less restrictive patent laws than those
upheld by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing
products.

Moreover, any patents issued
to us may not provide us with meaningful protection, or others